インターベンショナルオンコロジーデバイス市場- 世界の産業規模、シェア、動向、機会、予測、製品別、手技別、がんタイプ別、地域別、競合別、2019～2029年

インターベンショナルオンコロジーデバイスの世界市場は、2023年に25億4,000万米ドルと評価され、2029年のCAGRは7.86%で、予測期間中に目覚ましい成長を予測しています。

さまざまな種類のがんの有病率の上昇とライフスタイルの進化が、インターベンショナルオンコロジーデバイス市場の成長に大きく寄与しています。これらの機器は、画像ガイダンスの下で行われる低侵襲的な処置によって、がんの診断と治療を容易にします。さらに、多様ながん種の治療を目的とした腫瘍学技術の進歩は、入院期間の短縮、痛みの軽減、感染リスクの低下、術後ケアの最小化、回復の促進といった需要と相まって、市場の拡大をさらに後押ししています。さらに、医療セグメントにおける研究開発活動の活発化と政府規制の導入が、市場の成長を後押ししています。

主要市場の促進要因

がんの有病率と罹患率の上昇

低侵襲技術の進歩

画像誘導治療に対する需要の増加

低侵襲治療への嗜好

主要市場課題

保険償還の制限

技術コストの高さ

主要市場動向

医療インフラの拡大

戦略的提携パートナーシップ

セグメント別洞察

製品別洞察

手技別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 インターベンショナルオンコロジーデバイスの世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別（塞栓デバイス、アブレーションデバイス、サポートデバイス）
  • 手技別（熱腫瘍アブレーション、非熱腫瘍アブレーション、経カテーテル的動脈化学塞栓術（TACE）、経カテーテル的動脈放射塞栓術（TARE）、経カテーテル的動脈塞栓術（TAE））
  • がんタイプ別（肝臓、腎臓、肺、骨、その他）
  • 企業別（2023年）
  • 地域別
• 市場マップ

第6章 北米のインターベンショナルオンコロジーデバイス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 手技別
  • がんタイプ別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のインターベンショナルオンコロジーデバイス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 手技別
  • がんタイプ別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のインターベンショナルオンコロジーデバイス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 手技別
  • がんタイプ別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のインターベンショナルオンコロジーデバイス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 手技別
  • がんタイプ別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのインターベンショナルオンコロジーデバイス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 手技別
  • がんタイプ別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と新国市場開拓

• 合併買収（存在する場合）
• 製品上市（存在する場合）

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Medtronic PLC
• Terumo Corporation
• Boston Scientific Corporation
• Merit Medical Systems, Inc.
• HealthTronics, Inc.
• Johnson Johnson
• Teleflex Inc.
• Angiodynamics Inc.
• MedWaves, Inc.
• Becton, Dickinson, and Company

第15章 戦略的提言

第16章 戦略的提言当社について免責事項

Global Interventional Oncology Devices Market was valued at USD 2.54 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.86% through 2029. The escalating prevalence of various cancer types and evolving lifestyles are key contributors to the growth of the interventional oncology device market. These devices facilitate the diagnosis and treatment of cancer through minimally invasive procedures conducted under image guidance. Additionally, advancements in oncology technology, aimed at treating diverse cancer types, coupled with the demand for shorter hospital stays, reduced pain, lower infection risks, minimal post-operative care, and accelerated recovery, further propel market expansion. Moreover, increased research and development activities in the healthcare sector, alongside the adoption of government regulations, fuel market growth.

Key Market Drivers

Rising Cancer Prevalence and Incidence Rates

The escalating prevalence and incidence rates of cancer on a global scale are driving forces propelling the growth trajectory of the interventional oncology devices market. With cancer continuing to pose a significant health challenge worldwide, the number of individuals diagnosed with the disease is steadily increasing each year. This rise in cancer cases has created a pressing demand for sophisticated interventional oncology devices capable of facilitating the diagnosis, treatment, and management of diverse cancer types.

As the burden of cancer intensifies, there is a critical need for innovative medical solutions that can effectively address the complexities associated with the disease. Consequently, the market for interventional oncology devices is experiencing notable expansion, driven by the imperative to develop advanced technologies capable of meeting the evolving needs of healthcare providers and patients alike.

The growing prevalence of cancer underscores the urgency for the development and adoption of cutting-edge interventional oncology devices that can enhance diagnostic accuracy, improve treatment outcomes, and optimize disease management strategies. Against this backdrop, the interventional oncology devices market is poised for significant growth as stakeholders strive to meet the escalating demand for innovative solutions that can effectively combat the global cancer burden.

Advancements in Minimally Invasive Technologies

Technological advancements in minimally invasive techniques have sparked a revolution in cancer treatment paradigms, significantly transforming the landscape of oncological care. With the advent of interventional oncology devices, clinicians now possess powerful tools that allow for the execution of precise procedures with minimal disruption to surrounding tissues. This represents a notable departure from conventional surgical interventions, offering patients access to less invasive treatment options that promise reduced trauma and enhanced recovery.

Central to these advancements are the development and refinement of novel imaging modalities, which afford clinicians unprecedented insights into the intricate anatomical structures affected by cancer. These cutting-edge imaging techniques enable healthcare professionals to navigate complex treatment scenarios with unparalleled precision, enhancing treatment efficacy while minimizing collateral damage.

In addition to imaging innovations, the evolution of catheter-based devices has played a pivotal role in shaping the landscape of interventional oncology. These sophisticated devices empower clinicians to deliver targeted therapies directly to tumour sites, precisely modulating treatment delivery and maximizing therapeutic efficacy. By harnessing the capabilities of catheter-based interventions, clinicians can effectively combat cancer with unparalleled precision, offering patients tailored treatment regimens tailored to their unique disease profiles.

Driven by these transformative technological advancements, the adoption of interventional oncology devices is rapidly gaining momentum across the globe. As healthcare providers increasingly recognize the benefits of minimally invasive approaches in cancer treatment, the demand for these innovative devices continues to soar. With their unparalleled precision, enhanced therapeutic efficacy, and reduced patient morbidity, interventional oncology devices are poised to shape the future of cancer care, offering patients access to safer, more effective treatment options that promise to revolutionize the fight against cancer.

Increasing Demand for Image-Guided Therapies

Image-guided therapies have emerged as indispensable tools in the battle against cancer, offering clinicians the ability to precisely target tumours while sparing healthy tissues from harm. At the forefront of this innovative approach are interventional oncology devices, which leverage advanced imaging technologies to guide therapeutic interventions with unparalleled precision and accuracy. Techniques such as radiofrequency ablation (RFA), microwave ablation (MWA), and transarterial chemoembolization (TACE) rely on real-time imaging feedback to deliver targeted treatments directly to tumour sites, minimizing collateral damage and optimizing therapeutic outcomes.

The surging demand for image-guided therapies reflects their exceptional efficacy and safety profile, driving robust growth in the market for interventional oncology devices. As clinicians increasingly recognize the benefits of these minimally invasive techniques in the diagnosis and treatment of cancer, the adoption of interventional oncology devices continues to accelerate worldwide.

Preference for Minimally Invasive Procedures

The preference for minimally invasive procedures in cancer treatment is on the rise among patients and healthcare providers alike, driven by a multitude of compelling benefits. These include shorter hospital stays, diminished pain levels, lower risk of complications, and expedited recovery times, all of which significantly enhance patient outcomes and satisfaction. Interventional oncology devices play a pivotal role in meeting this demand by offering minimally invasive treatment alternatives that are particularly well-suited for patients ineligible for surgery or those seeking to circumvent more invasive interventions. As the trend towards minimally invasive approaches continues to gain traction, the global adoption of interventional oncology devices is poised for considerable growth.

Key Market Challenges

Reimbursement Limitations

Limited reimbursement coverage for interventional oncology procedures and devices represents a significant challenge in the Global Interventional Oncology Devices Market. Reimbursement policies vary across healthcare systems and regions, resulting in inconsistent coverage levels for interventional oncology treatments. The lack of adequate reimbursement can deter healthcare providers from adopting these technologies, limit patient access to innovative therapies, and hinder market growth. Addressing reimbursement limitations requires collaboration among stakeholders to advocate for favorable reimbursement policies and demonstrate the clinical and economic value of interventional oncology devices.

High Cost of Technology

The high cost associated with interventional oncology devices poses a significant barrier for market stakeholders across the globe. Developing and manufacturing these advanced medical devices requires substantial investments in research, technology, and production infrastructure. Companies invest significant financial resources and manpower in designing, testing, and refining interventional oncology devices to ensure they meet stringent quality standards and regulatory requirements.

Moreover, the implementation of interventional oncology technologies necessitates specialized training and infrastructure, further contributing to the overall cost of adoption. Healthcare providers require comprehensive training programs to acquire the necessary skills and expertise to effectively utilize these devices in clinical settings. Additionally, healthcare facilities need to invest in specialized equipment and infrastructure to support the safe and efficient use of interventional oncology devices during procedures.

The high upfront costs associated with acquiring interventional oncology devices may deter healthcare facilities, particularly those operating in resource-constrained settings, from making investments in these technologies. Limited financial resources and budgetary constraints may hinder healthcare organizations' ability to procure expensive medical equipment, limiting their access to advanced interventional oncology solutions.

Key Market Trends

Expanding Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in emerging markets, marks a pivotal development fostering greater accessibility to advanced medical technologies, including interventional oncology devices. Governments and healthcare organizations worldwide are actively investing in the establishment and enhancement of healthcare facilities equipped with state-of-the-art diagnostic and treatment modalities, geared towards addressing the escalating burden of cancer. By bolstering the availability of these cutting-edge resources, the expansion of healthcare infrastructure serves to facilitate broader utilization of interventional oncology devices, consequently propelling market growth within these regions and beyond.

Strategic Collaborations Partnerships

Collaboration among industry players, healthcare institutions, and research organizations plays a pivotal role in driving innovation and fostering market expansion within the interventional oncology devices sector. Through strategic partnerships, these stakeholders synergize their resources, expertise, and insights to spearhead the development of cutting-edge technologies, conduct robust clinical trials, and devise effective market access strategies. By harnessing synergies and complementary strengths across diverse entities, collaborative endeavors accelerate the pace of advancement and adoption of interventional oncology devices across global markets. These partnerships serve as catalysts for accelerating innovation, enhancing patient care, and ultimately shaping the trajectory of the interventional oncology devices industry.

Segmental Insights

Product Insights

Based on the product, ablation devices stand out as a dominant force in the global market. Ablation devices play a crucial role in the treatment of cancer by precisely targeting and destroying tumours using thermal or non-thermal energy sources. These devices offer minimally invasive alternatives to surgery and traditional cancer treatments, making them increasingly preferred by patients and healthcare providers alike.

The dominance of ablation devices in the global interventional oncology devices market is attributed to several factors. Ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, have demonstrated efficacy in treating a wide range of solid tumours, including liver, lung, kidney, and bone tumours. These devices are versatile and can be used to treat tumours of varying sizes and locations within the body.

Ablation devices offer several advantages over traditional treatment modalities, such as surgical resection and chemotherapy. They allow for targeted tumour destruction while minimizing damage to surrounding healthy tissues, resulting in fewer complications and faster recovery times for patients. Moreover, ablation procedures can often be performed on an outpatient basis, reducing hospitalization costs and improving patient comfort and convenience.

Procedure Insights

Based on the Procedure segment, thermal tumour ablation emerges as a dominant force in the global market for interventional oncology devices. Thermal tumour ablation involves the destruction of tumours through the application of heat generated by various energy sources, such as radiofrequency, microwave, or laser energy. This technique is highly effective in treating solid tumours located in different organs of the body, including the liver, kidney, lung, and bone.

The dominance of thermal tumour ablation in the global interventional oncology devices market can be attributed to several factors. Thermal ablation techniques have demonstrated high efficacy in achieving complete tumour destruction while minimizing damage to surrounding healthy tissues. This makes them a preferred choice for patients who are not suitable candidates for surgery or who prefer less invasive treatment options.

Thermal ablation procedures offer several advantages over traditional cancer treatments, such as surgical resection and chemotherapy. They are associated with shorter hospital stays, reduced post-procedural pain, and faster recovery times, leading to improved patient outcomes and satisfaction. Moreover, thermal ablation can often be performed on an outpatient basis, resulting in lower healthcare costs and greater convenience for patients.

Regional Insights

The dominance of the Global Interventional Oncology Devices Market is notably led by North America. Several factors contribute to North America's prominent position in this market. The region benefits from a highly developed healthcare infrastructure, equipped with state-of-the-art medical facilities and advanced diagnostic and therapeutic technologies. North America boasts a strong emphasis on research and development, with significant investments in innovative medical technologies and treatments.

Favourable reimbursement policies and regulations in North America support the adoption and utilization of interventional oncology devices, facilitating access to these advanced medical interventions for patients. Moreover, a large patient population diagnosed with various types of cancers drives the demand for interventional oncology devices in North America. Strategic collaborations between industry players, healthcare providers, and research institutions in North America foster innovation and drive market growth. These partnerships enable the development of cutting-edge technologies and the conduct of clinical trials, ultimately contributing to the advancement of interventional oncology devices.

Key Market Players

Medtronic PLC

Terumo Corporation

Boston Scientific Corporation

Merit Medical Systems, Inc.

HealthTronics, Inc.

Johnson Johnson

Teleflex Inc.

Angiodynamics Inc.

MedWaves, Inc.

Becton, Dickinson, and Company

Report Scope:

In this report, the Global Interventional Oncology Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Interventional Oncology Devices Market,By Product:

• Embolization Devices
• Ablation Devices
• Support Devices

Interventional Oncology Devices Market,By Procedure:

• Thermal Tumor Ablation
• Non-thermal Tumor Ablation
• Transcatheter Arterial Chemoembolization (TACE)
• Transcatheter Arterial Radioembolization (TARE)
• Transcatheter Arterial Embolization (TAE)

Interventional Oncology Devices Market,By Cancer Type:

• Liver
• Kidney
• Lung
• Bone
• Others

Interventional Oncology Devices Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Interventional Oncology Devices Market.

Available Customizations:

Global Interventional Oncology Devices market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, and Trends

4.Voice of Customer

5.Global Interventional Oncology Devices Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Product (Embolization Devices, Ablation Devices, Support Devices)
  • 5.2.2.By Procedure (Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE), Transcatheter Arterial Embolization (TAE))
  • 5.2.3.By Cancer Type (Liver, Kidney, Lung, Bone, Others)
  • 5.2.4.By Company (2023)
  • 5.2.5.By Region
• 5.3.Market Map

6.North America Interventional Oncology Devices Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Product
  • 6.2.2.By Procedure
  • 6.2.3.By Cancer Type
  • 6.2.4.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Interventional Oncology Devices Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Product
      • 6.3.1.2.2.By Procedure
      • 6.3.1.2.3.By Cancer Type
  • 6.3.2.Mexico Interventional Oncology Devices Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Product
      • 6.3.2.2.2.By Procedure
      • 6.3.2.2.3.By Cancer Type
  • 6.3.3.Canada Interventional Oncology Devices Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Product
      • 6.3.3.2.2.By Procedure
      • 6.3.3.2.3.By Cancer Type

7.Europe Interventional Oncology Devices Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Product
  • 7.2.2.By Procedure
  • 7.2.3.By Cancer Type
  • 7.2.4.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.France Interventional Oncology Devices Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Product
      • 7.3.1.2.2.By Procedure
      • 7.3.1.2.3.By Cancer Type
  • 7.3.2.Germany Interventional Oncology Devices Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Product
      • 7.3.2.2.2.By Procedure
      • 7.3.2.2.3.By Cancer Type
  • 7.3.3.United Kingdom Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Product
      • 7.3.3.2.2.By Procedure
      • 7.3.3.2.3.By Cancer Type
  • 7.3.4.Italy Interventional Oncology Devices Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Product
      • 7.3.4.2.2.By Procedure
      • 7.3.4.2.3.By Cancer Type
  • 7.3.5.Spain Interventional Oncology Devices Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Product
      • 7.3.5.2.2.By Procedure
      • 7.3.5.2.3.By Cancer Type

8.Asia-Pacific Interventional Oncology Devices Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Product
  • 8.2.2.By Procedure
  • 8.2.3.By Cancer Type
  • 8.2.4.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Interventional Oncology Devices Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Product
      • 8.3.1.2.2.By Procedure
      • 8.3.1.2.3.By Cancer Type
  • 8.3.2.India Interventional Oncology Devices Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Product
      • 8.3.2.2.2.By Procedure
      • 8.3.2.2.3.By Cancer Type
  • 8.3.3.South Korea Interventional Oncology Devices Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Product
      • 8.3.3.2.2.By Procedure
      • 8.3.3.2.3.By Cancer Type
  • 8.3.4.Japan Interventional Oncology Devices Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Product
      • 8.3.4.2.2.By Procedure
      • 8.3.4.2.3.By Cancer Type
  • 8.3.5.Australia Interventional Oncology Devices Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Product
      • 8.3.5.2.2.By Procedure
      • 8.3.5.2.3.By Cancer Type

9.South America Interventional Oncology Devices Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Product
  • 9.2.2.By Procedure
  • 9.2.3.By Cancer Type
  • 9.2.4.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Interventional Oncology Devices Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Product
      • 9.3.1.2.2.By Procedure
      • 9.3.1.2.3.By Cancer Type
  • 9.3.2.Argentina Interventional Oncology Devices Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Product
      • 9.3.2.2.2.By Procedure
      • 9.3.2.2.3.By Cancer Type
  • 9.3.3.Colombia Interventional Oncology Devices Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Product
      • 9.3.3.2.2.By Procedure
      • 9.3.3.2.3.By Cancer Type

10.Middle East and Africa Interventional Oncology Devices Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Product
  • 10.2.2.By Procedure
  • 10.2.3.By Cancer Type
  • 10.2.4.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Interventional Oncology Devices Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Product
      • 10.3.1.2.2.By Procedure
      • 10.3.1.2.3.By Cancer Type
  • 10.3.2.Saudi Arabia Interventional Oncology Devices Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Product
      • 10.3.2.2.2.By Procedure
      • 10.3.2.2.3.By Cancer Type
  • 10.3.3.UAE Interventional Oncology Devices Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Product
      • 10.3.3.2.2.By Procedure
      • 10.3.3.2.3.By Cancer Type

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Merger Acquisition (If Any)
• 12.2.Product Launches (If Any)
• 12.3.Recent Developments

13.Porters Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Products

14.Competitive Landscape

• 14.1.Medtronic PLC
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (As Reported)
  • 14.1.5.Recent Developments
  • 14.1.6.Key Personnel Details
  • 14.1.7.SWOT Analysis
• 14.2.Terumo Corporation
• 14.3.Boston Scientific Corporation
• 14.4.Merit Medical Systems, Inc.
• 14.5.HealthTronics, Inc.
• 14.6.Johnson Johnson
• 14.7.Teleflex Inc.
• 14.8.Angiodynamics Inc.
• 14.9.MedWaves, Inc.
• 14.10.Becton, Dickinson, and Company

15.Strategic Recommendations

16.About Us Disclaimer